DO WHAT YOU SAY !!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ILUS ! THE TIDE IS TURNING ! Hang-on-to-your-hats-folks !!
VeeMost Technologies Retains Amsterdam Group Public Relations - Updated
Press Release | 04/21/2023
Leading IT Solutions Provider to Showcase The Evolutionary Nature of Threats and Opportunities In Digital Infrastructure Resilience In 2023 And Company’s Role At The Vanguard Of Addressing Them
Red Bank, NJ, April 21, 2023 (GLOBE NEWSWIRE) -- VeeMost Technologies Holdings, Inc. formerly, Global Developments Holdings, Inc. (OTC: GDVM), a publicly listed innovative cloud/cybersecurity global solutions and digital transformation services provider with locations in the United States, India, and West Africa, has announced that the company has retained the international public relations and strategic communications firm, the Amsterdam Group, to bolster the former’s positioning at the forefront of addressing challenges, opportunities and optimization techniques throughout the seismically shifting digital infrastructure sector.
“Businesses from throughout the community of global enterprise undertook a forced period of introspection at the onset of the COVID-19 pandemic,” stated Melvin, Founder and CEO of VeeMost Technologies. “We are primed for the surge in digital transformation demands which the world of work is presently experiencing. That world is changing and make no mistake – so are the threats to ever-digitizing business alongside it. Vigilance to ensure scalability in operations and consistent growth is today’s prerequisite. We look forward to working with Sam and the Team at Amsterdam Group to showcase our over 20 years of industry experience across the value-chain, providing end-to-end strategies and counsel to customers both well-versed and presently undergoing enterprise digital transformation”.
VeeMost Technologies specializes in architecting, deploying, and managing secure digital solutions and platforms for customers to accelerate and enhance business efficiencies for increased profitability. Their counsel ensures that VeeMost customers are expertly leveraging boons in next-generation technology to optimize, build, and effectively run a resilient business operation and culture, while driving development throughout the process.
Amsterdam Group is a boutique public relations firm, with operations across the United States and globally. The company provides integrated global communications strategies, media engagement, digital branding, and advocacy driven campaigns that are tailored to the needs of each individual client and works collaboratively with those clients to relay their achievements and ambitions to the world.
“It is a privilege to partner with the dynamic Team at VeeMost Technologies and support their international endeavors in ‘change management’; driving enterprise infrastructure resilience to external shocks, each day becoming a consistently growing priority for businesses cross-sector of the modern age”, stated Sam Amsterdam, Founder and President of Amsterdam Group Public Relations. “We encourage VeeMost Technology customers and those seeking the suite of services which the organization has on offer to stay tuned for exciting developments in this intriguingly unique space”.
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.
CONTACT:
VeeMost Technologies, LTD
info@veemost.com
GDVM ! NOW YOU BE NICE ! Just don't ring the wrong door bell !! For a BEER .....get-it-get-er-done. HE-HAW !!
GDVM ! I LOVE SWEETHEARTS ! Don't get me wrong we are in a worthless chat ... if im lying .... im dying.
GDVM ! THE SITE WAS DOWN ! Pay attention i don't want to be tied to worthless companies ever when the tweet came-out there site was down an looked worthless... simple we want good stuff.. simple..... if im lying ... im dying.
GDVM ! LOOKING GOOD ! Site coming back-up ! Here you you go ... looking better....somebody paying attention.... https://www.datanyze.com/companies/amsterdam-group-public-relations/347439178 if im lying...im dying.
THIS IS CHIT I DONT EXPECT OUT-OF- A-COMPANY-TIED-TO-CISCO!! DO BETTER !! Fix-it .....if im lying....im dying.
GDVM !! THIS SAYS IT ALL !! https://www.datanyze.com/companies/amsterdam-group-public-relations/347439178
ILUS ! BUYING A BUNCH IN THIS AREA ! We might see .02 that's o.k. i sold most in the .10 an am proud an glad to buy back in the .03 cent area ....unreal market cap here. Yes i will load the truck at .02 area ....if im lying....im dying.
GDVM ! THIS IS NOT GOOD ! This all you got !! This is not really worth the tweet really i would expect much better... from a CISCO partner i believe that's why you saw price come back down in a hurry. ... if he had more i think he would rather tweet-it...... if im lying ... im dying.
GDVM !! CAN YOU FIND VEEMOST !! On the CISCO web site ! Under partners we are Premier
Integrator soon to be gold . https://locatr.cloudapps.cisco.com/WWChannels/LOCATR/pf/index.jsp#/?locale=en-US&location=United+States&role=Integrator .....if im lying....im dying.
GDVM ! I DONT BELIEVE ! I have seen this before >> https://veemost.com/tag/cisco/ >> maybe setting the stage for new news either way they have CISCO permission....if im lying .... im dying.
GDVM ! NO TRADING ! That's what the mm"s want with this spread somethings-up !.....jmo
GDVM ! UNREAL ALMOST A PENNY ! Spread whats-up ? CROOKED....Should be stopped...unreal...if im lying....im dying..
GDVM !! SO CHINOMSO PEARL ! Is AKA Chinomso Pearl Ejiogu an works for AVIT a gold partner to CISCO .. https://www.avitgroup.com/ so who is Nneoma Ejiogu who also works at Veemost ?
https://www.linkedin.com/in/dominicmbah?trk=public_profile_browsemap
https://ng.linkedin.com/in/ikechukwu-okorafor-aa8426123?trk=public_profile_browsemap
https://ng.linkedin.com/in/nneoma-ejiogu-926995138?trk=public_profile_browsemap
https://ng.linkedin.com/in/chidi-osuji-081a4ba2
https://ng.linkedin.com/in/ikechukwu-okorafor-aa8426123?trk=public_profile_browsemap&original_referer=https%3A%2F%2Fng.linkedin.com%2Fin%2Fchidi-osuji-081a4ba2
https://www.linkedin.com/in/eze-uba-a7a2451b5?trk=public_profile_browsemap&original_referer=https%3A%2F%2Fng.linkedin.com%2F
This one has the same last name as are CEO an works for AVIT....o-my .... if im lying....im dying.
https://www.linkedin.com/in/chinomso-ejiogu?trk=public_profile_browsemap
https://www.linkedin.com/company/avit-group?trk=public_profile_experience-item_profile-section-card_image-click&original_referer=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fchinomso-ejiogu%3Ftrk%3Dpublic_profile_browsemap
Wonder how many employees Veemost has. I sure i missed some.
Wilmington, DE, Feb. 14, 2023 (GLOBE NEWSWIRE) — Global Developments Holdings, Inc. (OTC: GDVM) and VeeMost Technologies, LTD have entered into a merger agreement through the exchange of preferred shares. As a result of the merger, Global Developments Holdings, Inc. has been renamed to VeeMost Technologies Holdings, Inc., and an application has been submitted to FINRA to change the issuer’s name, ticker symbol, and CUSIP.
Founded in 2002, VeeMost is a team of experienced industry leaders and professionals led by its chief executive officer, Mr. Melvin Ejiogu, who holds a bachelor’s degree in Business Administration with a specialization in Corporate Finance from the University of Akron, Ohio. In addition to having over 25 years of experience in the technology industry, Melvin holds numerous top-level I.T certifications, including the Cisco Certified Internetwork Expert (CCIE) certification.
Melvin has achieved success at multiple IT organizations including his prior partnership with Fit Technologies in Cleveland, Ohio. In this role, he served as Director of Business Development and Director of Technology Engineering, contributing significantly to the company’s growth and success. Melvin also served with AT&T Labs as a Lead Principal Architect & Designer. There, he led a highly specialized team of experts and was crucial in the design, implementation, and delivery of customized and secured network infrastructures, products, and solutions to large government agencies and enterprises.
In his first full year back at VeeMost as CEO and President, Melvin has built a strong foundation. He has set his sights on replicating his success at VeeMost and taking the company to new heights. As a result of this vision, VeeMost has made substantial additions to its engineering and sales teams and has been recognized as a Cisco premier partner and integrator. Furthermore, during the past eight months, VeeMost has achieved four Cisco advanced specializations: Advanced Enterprise Network Architecture, Advanced SP Architecture, Advanced Collaboration Architecture, and Advanced Security Architecture. VeeMost has become one of the few technology companies nationwide to achieve four or more Cisco advanced specializations, putting it on the path to becoming a Cisco Gold Integrator Partner.
VeeMost is committed to becoming a strategic partner for Cisco and other industry leaders by providing deep technical expertise in a variety of disciplines. VeeMost will also continue to achieve a high level of customer satisfaction by harnessing the power of the cloud and automation, helping organizations achieve enterprise growth and address cybersecurity concerns, virtual work requirements, application cloud modernization, infrastructure requirements, and more.
Worldwide spending on public cloud services in 2022 was $490.3 billion, and it is forecasted to increase by 21% in 2023. Aiming to capture a significant portion of the cloud market share, VeeMost will be launching its own innovative cloud services and solutions in the second quarter of 2023, making it publicly available to organizations and consumers. Furthermore, VeeMost will continue to provide full lifecycle management services for customers’ digital transformation journeys to the cloud. This service includes initial consultation and assessment and ends with full migration and management of cloud services, utilizing an iterative continuous improvement approach to infrastructure modernization.
As a result of cyber security incidents increasing at an exponential rate, organizations spent a collective $188.3 billion on information security products and services in 2022. In comparison with last year, cyber security spending is expected to increase by 12.4%. VeeMost has strategic alliances with most industry-leading security vendors, including Palo Alto Networks, Cisco Systems, and many more. In addition to providing strategic consulting and planning services, VeeMost offers implementation services, managed services, and technical services to organizations seeking to mitigate cyber security threats, meet regulatory requirements, and keep their businesses running smoothly. Our 24x7x365 NOC/SOC operation monitors our customers’ networks and security infrastructures, detects threats using AI and machine learning algorithms, and mitigates issues immediately to ensure seamless operations.
Due to VeeMost’s strategy on multi-year and long-term revenue streams and a current client retention rate of over 98%, the company is well positioned for short-, medium-, and long-term market penetration success and explosive growth. Aside from organic growth, VeeMost intends to acquire technology companies and cyber security companies as wholly owned subsidiaries. We are currently in active discussions with two potential acquisition targets with whom we anticipate reaching an agreement in the near future.
In the words of VeeMost’s CEO Melvin Ejiogu, “I am ecstatic with what we accomplished in 2022 and look forward to what lies ahead in 2023, which appears to be shaping up to be an extremely successful year for the company. Over the years, VeeMost has developed a high level of technical expertise across the entire Cisco Portfolio, as well as multiple advanced specializations. Additionally, we have expanded our relationship with other leading vendors, such as Palo Alto. These achievements demonstrate and validate our ability to collaborate and innovate technology solutions at scale for our customers and deliver a high level of customer support.”
Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “continue,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company’s control.
https://veemost.com/stock-info/
GDVM ! LOVE MY FELLOW SHARE HOLDERS ! Your going to enjoy life....if im lying...im dying....
GDVM ! FOLKS WILL LEARN ! This is how you build a real company cant wait to see the real news ...... this will set the stage for many that want to build a real company.....if you read between the lines are CEO just saved VEEMOST a ton of tax money.... if im lying....im dying.
GDVM ! THIS IS HUGE ! I didn't believe that one but i did when i seen it here ....unreal....if im lying...im dying. This is a news event we will hear soon.
https://www.otcmarkets.com/stock/GDVM/security
GDVM ! BUST-IT THIS COMING WEEK ! Just hit play.....i see one on the daily chart as well !
https://school.stockcharts.com/doku.php?id=chart_analysis:chart_patterns:symmetrical_triangle_continuation
GDVM ! THIS IS HUGE ! Learn biz lower your taxes.....simple...is it Monday yet !!
https://www.delawareregisteredagent.com/delaware-resources/amend-authorized-stock-and-lower-franchise-tax
GDVM ! NOTHING WE DID NOT KNOW-ALREADY ! Going to shovel the sidewalk. Monday we might get something with 10-k-out an attorney letter .......if im lying....im dying.
GDVM ! GOOD FOLKS INDEED ! Not like many pinky CEO "s The individual responsible for the preparation of the Disclosure Statement contained in the Information was
Melvin Ejiogu, the President, who I have also personally communicated with.
The Issuer's transfer agent is Pacific Stock Transfer Co., which is registered with the Securities and
Exchange Commission. I relied upon information provided by Issuer Direct Corporation to confirm the number of
outstanding shares set forth in the Information.
To the best of my knowledge, after inquiry of management and the directors of the Issuer, the Issuer, nor
any 5% holder, nor counsel, is currently under investigation by any federal or state regulatory authority for any
violation of federal or state securities laws.
The Issuer is not a “shell company” as defined in Rules 405 of the Securities Act of 1933 and 12b-2 of the
Exchange Act of 1934.
No person other than the OTC Markets Group is entitled to rely on this letter; however, OTC Markets
Group is granted full and complete permission and rights to publish the letter through the OTC Disclosure & News
Service for public viewing.
This letter is meant to cover and speak in regard to the above-referenced report periods only and shall not
apply for any other period.
Sincerely,
John J. Brannelly
GDVM ! DONT BE CONFUSED BY THAT ! We are veemost.....if im lying ... im dying.
VTGN ! NEWS ! FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
Vistagen plans to use the LSAS as the primary efficacy endpoint for a Phase 3 clinical study designed to evaluate fasedienol as a treatment for the overall control of symptoms of social anxiety disorder (SAD)
FDA provides helpful guidance on key aspects of potential NDA-enabling development plan in SAD
March 30, 2023 08:30 AM Eastern Daylight Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced positive feedback from its recent engagement with the U.S. Food and Drug Administration (FDA) regarding the use of the Liebowitz Social Anxiety Scale (LSAS) as the primary endpoint for future clinical studies designed to evaluate the efficacy of a treatment for the overall control of symptoms of social anxiety disorder (SAD). With FDA feedback confirming the acceptable use of the LSAS as a primary efficacy endpoint, Vistagen is positioned to finalize key components of its potential New Drug Application (NDA)-enabling development program for fasedienol for treatment of SAD. Dr. Michael R. Liebowitz, a Columbia University psychiatrist, former director and founder of the Anxiety Disorders Clinic at the New York State Psychiatric Institute and current Managing Director of The Medical Research Network LLC in New York City, is the innovator of the LSAS and is the Principal Investigator in Vistagen’s new FEARLESS program, the Company’s Phase 3 development program for fasedienol for treatment of SAD.
“With positive feedback from the FDA, we’re focused on advancing a clinical study design with the Liebowitz Social Anxiety Scale as the primary endpoint to study the real-world effects of fasedienol over time,” said Shawn Singh, Chief Executive Officer of Vistagen. “This is an important step forward, especially as SAD is becoming even more prevalent in a post-COVID world. With today’s announcement, we believe Vistagen has a clear path for the continued development of fasedienol and we are more committed than ever in our mission to create safe medicines that can improve mental health.”
The LSAS
Dr. Liebowitz innovated the LSAS in the mid-1980s. Three medications, two SSRIs (paroxetine and sertraline) and one SNRI (venlafaxine extended release), are currently marketed in the U.S. for the treatment of SAD on the basis of registrational trials and subsequent FDA approvals in which the LSAS was the primary efficacy endpoint. Dr. Liebowitz was among the clinical investigators involved in the registrational efficacy trials for all of these drugs, and all of such registrational trials were positive.
The LSAS consists of 24 situations that commonly induce fear, anxiety and avoidance in SAD patients. The clinical rater asks SAD patients how fearful or anxious they felt in the past week during each of the 24 situations they experienced, or to imagine how anxious they would have been in any situation(s) not actually encountered. After rating fear and anxiety in each situation, the rater then asks how often the patient actually avoided, or would have avoided, each of the situations. This built-in internal verification between a patient's subjective feeling and actual behavior makes the LSAS unique when compared to other scales. Vistagen, in collaboration with Dr. Liebowitz, has developed a robust rater training and certification program for all clinicians assigned by the investigator to administer the LSAS in a Vistagen SAD study.
Fasedienol and the LSAS
The safety profile and potential for fasedienol to achieve overall reduction in symptoms of SAD and improvement in severity of the disorder, as measured by the LSAS, have been demonstrated in a placebo-controlled Phase 2 study after two weeks of use, as well as in a large open-label study over a period of one month and beyond. The Company believes these LSAS data suggest that studies involving multiple administrations of fasedienol over time, on an as-needed basis when subjects experience real-life, socially stressful situations, most accurately demonstrate the safety and efficacy potential of fasedienol in patients with SAD and the way fasedienol would be used by SAD patients, if approved. Each SAD patient is unique, and Vistagen believes an optimal SAD treatment is one that is individualized and tailored-to-fit by patients, as-needed, to help them engage in the anxiety-provoking situations they encounter in their daily lives with less fear and anxiety.
Additional Fasedienol Program Updates
FEARLESS-1 and PALISADE-2
Positive LSAS data from a placebo-controlled Phase 2 study and exploratory data from a large Phase 3 open label study corroborate that the LSAS is the psychometric scale best suited for assessing the efficacy of fasedienol in future studies. Both studies evaluated multiple administrations of fasedienol by SAD patients in a real-world environment over time and showed clinically meaningful improvements using the LSAS scale. The clinical data, together with fasedienol’s unique mechanism of action and pharmacological properties, support using the LSAS as the primary endpoint in the next potential Phase 3 study of fasedienol in SAD – FEARLESS-1. The Company also plans to include a second LSAS-based Phase 3 study and an open-label long term safety study in its potential NDA-enabling FEARLESS Phase 3 program for fasedienol in SAD. In addition to the positive FDA feedback regarding the use of the LSAS as the primary endpoint, the FDA also provided guidance on further characterizing the optimal fasedienol dosing strategy. The Company plans to have further protocol discussions with the FDA regarding additional dosing study(s), which the Company plans to conduct in parallel with FEARLESS-1 and potentially prior to commencement of the second LSAS-based Phase 3 study, to provide further foundational information about dosing frequency for purposes of labeling should fasedienol be approved.
Although the results of the interim analysis of PALISADE-2 indicated that continuation of the study would not be futile, Vistagen has determined the best course of action is to close the PALISADE-2 study given the expense, time, and methodological complexities involved in resuming PALISADE-2, including consistently administering the protocol for the single-dose, clinic-based public speaking challenge study across numerous sites. Considering the recent feedback from the FDA regarding use of the LSAS in future clinical studies, Vistagen will focus resources primarily on the planning and preparation for FEARLESS-1, a LSAS-based Phase 3 study of fasedienol for treatment of SAD. Topline results from the 140 subjects who completed PALISADE-2 are expected in the second half of 2023.
Exploratory Phase 2A Study in Adjustment Disorder with Anxiety
Adjustment disorder with anxiety (AjDA) is clinically understudied, difficult to diagnose, presents with highly variable symptoms across patients and has uncertain boundaries in patients with pre-existing psychiatric disorders. Vistagen’s small exploratory study in AjDA is believed to be the first ever randomized, double-blind, placebo-controlled Phase 2A study in the U.S. aimed at exploring the pharmacological treatment of AjDA, and the first clinical trial that evaluated the effects of a fixed dosing regimen of fasedienol, involving intranasal administration of 3.2 µg of fasedienol four times per day over four weeks. A total of 71 subjects were screened for the study, 41 were randomized, 7 discontinued, and 34 completed four weeks of treatment. The study, which was not designed to achieve statistical significance, did not demonstrate a clinically significant difference between fasedienol and placebo as measured on the clinician-rated Hamilton Anxiety Scale (HAM-A). Site variances and high drug and placebo response rates were observed, likely related to the various aspects of AjDA that make it challenging to study. The study of AjDA is complicated because the disorder is by definition temporary and self-resolving, making it difficult to identify the cause of clinical improvement or whether placebo played a role in any improvement observed. AjDA is a temporary stress reaction. The stress reaction typically starts within three months of an identifiable stressful situation, but because the disorder is directly linked to a stressor, once it ends, the anxiety reaction may also end, with or without treatment.
Fixed dosing of fasedienol four times per day over four weeks was safe and well tolerated, with no appreciable differences in treatment-emergent adverse effects (TEAEs) between fasedienol and placebo. All reported TEAEs were of mild or moderate severity, with no severe or serious TEAEs reported during the study. Headache was the most commonly reported TEAE, reported by 3 subjects (15.8%) on fasedienol and 2 subjects (9.1%) on placebo.
Despite the methodological challenges inherent in the exploratory Phase 2A study in AjDA, the Company believes fasedienol builds resilience against anxiety and reduces the cognitive and physical paralysis that occurs during moments of heightened anxiety and stressful situations. Results of the AjDA study may provide support for an as-needed (PRN) fasedienol dosing approach over time as the preferred mode of treatment. Vistagen believes fasedienol modulates autonomic activity and that taking fasedienol on demand, as-needed immediately before or during anxiety-provoking situations, instead of on a fixed schedule (as in the AjDA study), may be the best way to demonstrate the anti-anxiety, or anxiolytic, effects of fasedienol and if approved, the best way for patients to use the drug in the real world for the treatment of SAD.
About Fasedienol (PH94B)
Vistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational pherine nasal spray with a novel proposed mechanism of action (MOA) that regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system, without systemic distribution, potentiation of GABA-A or direct activity on CNS neurons in the brain. Vistagen is developing fasedienol in a Phase 3 program for the treatment of social anxiety disorder. Designed for intranasal administration in low microgram doses, the proposed novel MOA of fasedienol is fundamentally differentiated from all currently approved anti-anxiety medications, including all antidepressants and benzodiazepines.
About Social Anxiety Disorder
Social anxiety disorder (SAD) affects an estimated 25 million Americans. A person with SAD feels intense, persistent symptoms of anxiety or fear in certain social situations, such as meeting new people, making comments in a business meeting, dating, being on a job interview, answering a question in class, or talking to a cashier in a store. Doing common, everyday things in front of people causes profound anxiety or fear of being embarrassed, evaluated, humiliated, judged, or rejected. SAD can get in the way of going to work, attending school, or doing a wide variety of things in a situation that is likely to involve interpersonal interaction. It can lead to avoidance and opportunity costs that can significantly impact a person's employment and social activities and be very disruptive to their overall quality of life. SAD is commonly treated long-term with certain FDA-approved antidepressants, which have a slow onset of effect (several weeks) and provide limited therapeutic benefits, and benzodiazepines, which are not FDA-approved for the treatment of SAD. Both antidepressants and benzodiazepines have known side effects and significant safety concerns that may make them unattractive to individuals affected by SAD.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available for treatment of anxiety and depression. Vistagen’s product candidates belong to a new class of drugs known as pherines, which are designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can beneficially impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.Vistagen.com.
GDVM !! SHOW ME THE MONEY ! Believe me that's what we are always looking for .But not to confuse investors . You as a CEO would you not wait for the NAME CHANGE an SYMBOL CHANGE before showing your hand ? . Asking for a friend .....if you call a tweet a p.r. i beg-to differr......copeach Lets put the cart before the horse then tell everybody !! .....if im lying.....im dying.
GDVM ! WHAT IS SLED ! To kick things off, I wanted to start by defining what the SLED market entails and why understanding their independence is crucial to success. When we talk about SLED, we are talking about more than 90,000 different government organizations.
50 States
3,000+ Counties / Boroughs / Parishes
36,000+ Cities / Towns / Municipalities
12,000+ Public School Systems
2,000+ Higher Education Institutions
38,000+ Special Districts
What is important to remember about these thousands of organizations is that they are independent organizations. Cities, counties, and school districts each have unique needs and requirements — even if they are in the same geographic area. For example, the rules and regulations governing how the City of Los Angeles conducts procurements will be different than those of the County of Los Angeles.
Taking time to research and understand each organization’s position, needs and requirements and incorporating that knowledge in your messaging and go-to-market approach can be the differentiator you need to stand out against your competitors.
Delivering customized messages and developing go-to-market approaches for each of the individual organizations is not necessary, however. Developing segment-specific messaging that you can reuse will allow you to be more productive and reach more prospects with similar needs.
Naming conventions and nomenclature will vary from state to state, but in general, the functions of state and local government fall into one of these 9 market segments: Health & Human Services, Education, Transportation, General Government, Law Enforcement & Public Safety, Community Services, Environment, Legislate and Courts.
While each organization within these market segments is certainly unique, there are some common needs that spread across organizations. If we look at the Education market segment for example, Prince William County Public Schools and Fairfax County Public Schools are two separate entities but can both benefit from technology that helps them visualize the data in their learning management systems or protect their systems from ransomware attacks.
For vendors, this means that you can differentiate yourself from the competition by developing tailored messaging and go-to-market approaches that focus on the common priorities, needs and requirements within each segment, whether Health & Human Services or Transportation or any of the other market segments.
Conclusion
Developing go-to-market plans for 90,000 different organizations is just not feasible, but if you divide the market into segments and develop go-to-market plans and tailored messaging for the ones you want to target, the market becomes more accessible. And you can still approach each organization as an independent entity with appropriate messaging that will resonate with them.
GDVM ! RELAX HAVE FUN !! Enjoy folks your going to love life ! So fun !! ...if im lying....im dying.
GDVM ! THE WEEKLY CHART OMG ! Look at that Williams (14) when it turns hang-on-to-your-hats-folks ! Not pumping or trying not to but the MACD is like a rubber band an on the weekly its going to happen will it cross ?? We will see mms want to zero-it-out........if im lying......im dying.
GDVM ! GET READY MY FRIEND ! Be careful so easy to lose your shares mms know an love-it ! Don't sell-don't-sell-this chart could turn so-solid-so-quick....they do not want no attention here......simple....if im lying....im...dying
GDVM ! GLAD TO SEE THEM BIG BIDS BACK ! We might see another test of the low today tomorrow who knows . I got 70k today im getting up there in the mill share class like-you. In my eyes we will not bust .05 ever again. Yes looking around if we bust that .0758 again ....well..i see new all time highs !! Tomorrow will be telling !! We need something....a news article that would be nice ...even a paid one. Nice to see it is not a pump an dump with the d word with-it for sure! An the CEO is clamed-up-big-time-nice-to-see-unreal ! will not respond to fb no-more its like stfu !!....I....love-it !! Real company in the pennies no-way-all-scams-we-all-know-that!! What-a-hole-to-crawl-out-of ! Have-fun ! know i am.....if im lying....im dying >> Buys today >>
Filled Buy 29000 GDVM Limit 0.0621 -- -- 14:09:30 03/28/23
Filled Buy 39000 GDVM Limit 0.0621 -- -- 13:48:32 03/28/23
Hope you all got some ! buy low sell high....be very careful with this real company in the pennies unreal ! naq-here we come !!
GIDDY-UP !!
GDVM ! BIDS ARE HUGE ! Saw 7 mill + at .059 an 900k + at .0638 at the close was fast hammer time ......nice to see-em.....if im lying....im dying.
GDVM ! TAKES 5 BIZ-DAYS FOR SYMBOL CHANGE !! Looky here on SIVB.....if im lying....im dying.....giddy-up !!
https://www.otcmarkets.com/market-activity/corporate-actions